IL-15, IL-21 (subcutaneous delivery)

BNZ-2 selectively inhibits IL-15 and IL-21 and has showed potent in vivo activity. IL-15 is central in celiac disease and many other inflammatory diseases of the gut and recent research has demonstrated that IL-21 functions in tandem/synergistically with IL-15.